CytoSorbents Welcomes Thomas Shannon as New North American Marketing VP: A Strategic Move for DrugSorb™-ATR Launch
Exciting developments are underway at CytoSorbents Corporation as they strengthen their marketing leadership team.
Introduction to a Game-Changer
In a significant move to enhance its market presence in North America, CytoSorbents Corporation, a pioneering name in blood purification technology, has appointed Thomas Shannon as the Vice President of Marketing for the region. This strategic appointment comes as the company gears up for the launch of its innovative DrugSorb™-ATR, a device poised to transform the landscape of cardiothoracic surgery.
The Visionary Behind the Strategy
“We are excited to welcome Tom to the CytoSorbents team as we prepare for the potential launch of DrugSorb-ATR in the U.S. and Canada,” states Dr. Phillip Chan, CEO of CytoSorbents. With over 25 years of unique experience in marketing life-saving medical technologies, Shannon brings a wealth of knowledge that could be pivotal as the company embarks on this new journey.
A Track Record of Success
Shannon’s robust history in the medical device industry is second to none. Before joining CytoSorbents, he held key positions at esteemed companies:
- Genesee Biomedical: As VP of Sales and Marketing, he contributed to innovations for cardiac heart valve repair.
- Fresenius Medical Care: Developed the Heart and Lung Acute Care division and launched the groundbreaking ECMO life support device.
- Getinge (formerly Maquet): Successfully commercialized over 20 new products, including the market-leading CardioHelp® ECMO platform.
- Medtronic: Launched a range of products in anti-coagulation monitoring and blood pumps.
During his impressive career, Shannon spent 17 years as a healthcare practitioner, including 12 years as a cardiovascular perfusionist, granting him unparalleled insight into the needs of patients and surgical teams.
A Crucial Problem Demands Innovative Solutions
In his own words, Shannon emphasizes the critical challenges faced in cardiothoracic surgeries: “Intraoperative and postoperative bleeding in CABG patients… is a major problem that only continues to get worse.” With DrugSorb-ATR, CytoSorbents aims to tackle the significant complications arising when patients are on blood thinners like Brilinta®.
This device is a U.S. FDA Breakthrough medical device, specifically designed to aid in the management of perioperative bleeding. Expected regulatory outcomes in 2025 will be closely watched by both patients and practitioners eager for a solution to this pressing healthcare issue.
Future Innovations on the Horizon
CytoSorbents leverages cutting-edge biocompatible technologies, aimed ultimately at saving lives through effective blood purification. The challenges posed by severe conditions like sepsis, burn injury, and liver failure are formidable. Nevertheless, the company’s diverse product pipeline reflects a commitment to addressing these critical healthcare gaps.
About CytoSorbents Corporation
CytoSorbents Corporation (NASDAQ: CTSO) is at the forefront of blood purification technologies, utilized across various critical conditions in intensive care units and during complex surgical procedures. Their flagship product, CytoSorb®, has been approved in the European Union and is already making an impact in over 70 countries worldwide. With a commitment to innovation, they work tirelessly to ensure that every patient receives the best possible care.
Conclusion: A New Era for CytoSorbents
The future certainly looks bright for CytoSorbents with Thomas Shannon at the helm of their marketing efforts in North America. As they prepare for the launch of DrugSorb-ATR, the company’s focus on excellence and innovation promises to pave the way for improved patient outcomes in surgeries plagued by bleeding complications.
Stay updated on CytoSorbents’ journey by following their developments on their official website and social media channels.
For more information about CytoSorbents and its commitment to life-saving technologies, visit their website at CytoSorbents or follow them on Facebook and X.
This article presents a forward-looking take on the recent appointment within CytoSorbents and its significance for the medical industry, with strategic keywords to enhance SEO visibility.
